Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)
GHAPPcast
This is the official podcast of The Gastroenterology & Hepatology Advanced Practice Providers (GHAPP), an association is dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs). Through our peer-to-peer network, we seek to support their integral role in the specialty healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with gastrointestinal (GI) disorders and chronic liver disease (CLD).
Be sure to visit the podcast's website and support the creator: ghappcast.captivate.fm
Author
Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)
Category
Podcast website
Latest episode
Nov 17, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
GHAPPcast: Simplifying Access: Prior Authorization Part 2 25.03.2025 11:27
In Episode 2 of our Simplified Access Series, we continue our deep dive into practical strategies to streamline the prior authorization (PA) process and reduce delays in patient care. Nurse practitioners Tedra Gray and Allison Moser return alongside Jeff Dunn, PharmD, a veteran in managed care and president of a transparent PBM, to explore real-world solutions for improving first-attempt PA succes...
GHAPPcast: Simplifying Access: Prior Authorization Part 1 25.03.2025 12:04
Welcome to Episode 1 of our Simplified Access Series, where we explore real-world strategies to navigate prior authorizations and medication distribution challenges in hepatology and gastroenterology. In this conversation, hepatology nurse practitioners Allison Moser, Rush University Medical Center, Chicago, and Tedra Gray, Sinai, Chicago, are joined by Jeff Dunn, PharmD, a managed care veteran an...
Journal Club: Efficacy & Safety of Subcutaneous Guselkumab: 48-Week Results from the Phase 3 GRAVITI Study 18.03.2025 4:47
Thank you to Johnson & Johnson for your support of this Journal Club Video Module. The GRAVITI study provides compelling Phase 3 data on guselkumab, an IL-23 p19 subunit inhibitor, demonstrating its efficacy and safety in patients with moderate to severely active Crohn’s disease. In this Journal Club video module, Alison Moe, PA-C, from Atlanta Gastroenterology, breaks down the key findings, d...
GHAPPcast: The Clinical Utility of Guselkumab in UC 11.03.2025 26:52
Thank you to Johnson & Johnson for your support of this GHAPPcast episode. Join us for a compelling episode of GHAPPcast, the official podcast for advanced practice providers in gastroenterology and hepatology. In this episode, host Gabriella McCarty, NP-C, welcomes esteemed guest Sharon Dudley-Brown, PhD, a leading expert from Johns Hopkins and a professor at the University of Delaware. Toget...
KOL: What Are the Most Critical Updates in Cirrhosis Research That Clinicians Should Be Aware Of? 06.03.2025 4:02
Cirrhosis is often considered an irreversible liver disease, but is there a chance for early-stage reversal? In this episode, Janet Gripshover, CRNP, Nurse Manager for the Cedars-Sinai Liver Transplant Program, dives deep into the latest advancements in cirrhosis treatment, liver transplant eligibility, and the evolving landscape of transplantation. She discusses the critical role of early detecti...
KOL: How Can Healthcare Professionals Improve Patient Outcomes in Those with Cirrhosis? 04.03.2025 3:32
Cirrhosis is a progressive liver disease that requires early detection, effective management, and patient education to improve outcomes. In this video, Allison Moser, NP, a Transplant Hepatology Nurse Practitioner at Rush University Medical Center, shares key strategies for healthcare professionals to enhance patient care. She discusses the importance of early screenings for high-risk individuals,...
Journal Club: Efficacy and Safety of Guselkumab in Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results 27.02.2025 5:56
Explore the latest findings on Guselkumab as a maintenance therapy for moderate to severe ulcerative colitis from the Phase 3 QUASAR Maintenance Study. In this Journal Club video module, Shayla Schoenoff, PA-C, reviews key efficacy and safety outcomes in patients who demonstrated a clinical response to Guselkumab IV induction. The randomized, placebo-controlled trial assessed subcutaneous Guselkum...
FAQ: How does the guselkumab data align with the STRIDE II guidelines? 25.02.2025 2:43
Thank you to Johnson & Johnson for your support of this FAQ Video Module. In this video, Erin Darguzas, NP, from the Inflammatory Bowel Disease Center at Northwestern Medicine, discusses how Guselkumab data aligns with STRIDE II guidelines for monitoring IBD (Inflammatory Bowel Disease) patients over time. Developed by International Organization for the Study of Inflammatory Bowel Diseases (IO...
Medication Review: What are guselkumab's other FDA indications and how might that affect patient care? 20.02.2025 2:46
Thank you to Johnson & Johnson for your support of this Medication Review Video Module. In this video, Anne Feldman, NP, from Cleveland Clinic, discusses Guselkumab (Tremfya), an FDA-approved treatment for adults with moderate to severe ulcerative colitis, plaque psoriasis, and psoriatic arthritis. With promising Phase 3 clinical trial results, Guselkumab is expected to receive FDA approval fo...
KOL Interview: Can You Discuss Any Recent Breakthroughs in the Management of Cirrhosis? 19.02.2025 2:52
In this video, Sherona Bau, NP, at Pfleger Institute at UCLA, shares the latest advancements in cirrhosis management, including newly FDA-approved medications and updated AASLD (American Association for the Study of Liver Diseases) guidelines. While there are still limited medications specifically for cirrhosis, recent developments provide promising options for patients with liver disease. One key...
FAQ: What should patients know about living with cirrhosis? 17.02.2025 3:34
In this video, Janet Gripshover, CRNP, Nurse Manager at Cedars-Sinai Liver Transplant Program, discusses essential steps for managing cirrhosis to improve quality of life and longevity. The most critical action for anyone living with liver disease is to completely eliminate alcohol consumption, as alcohol accelerates liver damage, increases fibrosis, and raises the risk of decompensated cirrhosis,...
FAQ: What are predictive risk factors for disease severity in CD and UC? 13.02.2025 2:45
Thank you to Johnson & Johnson for your support of this FAQ Video Module. In this FAQ video module, Erin Darguzas, NP, Gastroenterology Specialist at Northwestern Medicine, discusses the predictive risk factors for disease severity in Crohn’s disease and ulcerative colitis. Over the past 15 years, researchers have identified multiple prognostic factors that can help predict disease progression...
FAQ: What lifestyle changes are essential for managing cirrhosis effectively? 12.02.2025 2:08
In this video, Sherona Bau, NP, from the Pfleger Liver Institute at UCLA, discusses the essential lifestyle changes for effectively managing cirrhosis. Maintaining a healthy lifestyle is key to slowing disease progression and preventing complications. One of the most critical recommendations is completely avoiding alcohol, as it accelerates liver damage and increases the risk of decompensation. A...
Journal Club: Guselkumab Efficacy & Safety in Moderate to Severe CD-GALAXI 2 & 3 Results 11.02.2025 4:33
Thank you to Johnson & Johnson for your support of this Journal Club Video Module. In this video, Jamie Brogan, NP, from Northwestern Medicine in Chicago, discusses the efficacy and safety of Guselkumab therapy for patients with moderate to severely active Crohn’s disease, highlighting results from the Galaxy 2 and Galaxy 3 trials. Guselkumab is a dual-acting IL-23p19 subunit inhibitor, design...
FAQ: How Can You Support a Shared Decision-Making Process With the Patient? 10.02.2025 2:35
In this video, Allison Moser, a transplant hepatology nurse practitioner at Rush University Medical Center, discusses the key principles of shared decision-making and how healthcare providers can better support their patients in making informed choices about their care. Shared decision-making is a collaborative approach that prioritizes communication, respect, and patient autonomy, ensuring that t...
Medication Review: What is the efficacy of guselkumab in ulcerative colitis and Crohn's disease? 06.02.2025 8:10
Thank you to Johnson & Johnson for your support of this Medication Review Video Module. In this comprehensive medication review, Peter Byrne, FNP, from South Denver Gastroenterology, discusses the efficacy of guselkumab in treating ulcerative colitis (UC) and Crohn’s disease (CD) based on key clinical trials, including Quasar and Galaxy 1. Guselkumab has demonstrated significant efficacy in tr...
FAQ: How can physicians better care for patients with cirrhosis? 05.02.2025 2:48
Sherona Bau, NP, at Pfleger Liver Institute, discusses the importance of providing effective care for patients with cirrhosis, which requires a proactive and comprehensive approach from healthcare providers, including physicians and advanced practice providers. Early diagnosis is crucial, as many patients with compensated cirrhosis remain asymptomatic. Using non-invasive testing, such as FibroScan...
Medication Review: What is the safety profile of guselkumab in ulcerative colitis and Crohn's disease? 04.02.2025 5:06
Thank you to Johnson & Johnson for your support of this Medication Review Video Module. In this medication review module, Peter Byrne, FNP at South Denver Gastroenterology, discusses the safety of guselkumab in the treatment of Ulcerative Colitis and Crohn's disease. The Quasar trial, a phase 3 double-blind study, evaluated the safety of guselkumab in patients with inadequate responses to conv...
Journal Club: Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study 30.01.2025 3:20
Thank you to Johnson & Johnson for your support of this Journal Club Video Module. In this Journal Club video module, Jamie Brogan, NP, from Northwestern, discusses findings from the Phase 2 GALAXI-1 Study, which evaluated guselkumab, a selective IL-23p19 antagonist, for the treatment of moderate-to-severe Crohn’s disease. This randomized, placebo-controlled study assessed intravenous guselkum...
GHAPPcast Part 3: Provider & Patient Support 29.01.2025 10:36
In this episode of GHAPPcast, Jordan Mayberry, a PA-C at UT Southwestern in Dallas, Texas, and Patrick Horne, a nurse practitioner from the University of Florida, dive deep into the support strategies for healthcare providers and patients managing chronic liver disease and cirrhosis. As a healthcare provider, it’s essential to rely on a variety of resources to stay up-to-date on the latest guideli...
FAQ: Is there a correlation of myeloid cells expressing CD64 and endoscopy disease severity? 28.01.2025 1:52
Thank you to Johnson & Johnson for your support of this FAQ Video Module. In this video module, Amy Stewart, NP, from Capital Digestive Care, in Washington, D.C., explores the potential correlation between CD64-expressing myeloid cells and endoscopic disease severity in patients with inflammatory bowel disease (IBD). CD64 is a plasma membrane receptor found on myeloid cells, a category of bloo...
GHAPPcast Part 2: Diagnosis and Management 24.01.2025 12:09
In this insightful GHAPPcast podcast, Patrick Horne, a nurse practitioner at the University of Florida, joins Jordan Mayberry, a physician assistant at UT Southwestern, to discuss the diagnosis and management of cirrhosis. They explore the latest diagnostic techniques, the role of non-invasive testing, and strategies for monitoring and managing cirrhosis patients to ensure the best possible care....
FAQ: Why is binding CD64+ important when discussing IL23 directed therapy? 23.01.2025 2:32
Thank you to Johnson & Johnson for your support of this FAQ Video Module. Join Sarah Enslin, PA-C, from the University of Rochester Medical Center, as she explores the latest advancements in CD64-positive cell targeting and IL-23-directed therapy. This innovative approach enhances the specificity and effectiveness of treatment for psoriasis, psoriatic arthritis, and inflammatory bowel disease...
GHAPPcast Part 1: Understanding Chronic Liver Disease and Cirrhosis 22.01.2025 10:09
In this GHAPP podcast episode, Jordan Mayberry, PA-C, and Patrick Horne, NP, dive deep into the complexities of chronic liver disease and its progression to cirrhosis. Drawing on over 11 years of experience in hepatology, Jordan and Patrick discuss the most common causes of liver disease, including viral hepatitis (Hepatitis B & C), alcohol-related liver disease, and metabolic-associated steat...
Medication Review: How is guselkumab dosed in IBD? 21.01.2025 3:06
Thank you to Johnson & Johnson for your support of this Medication Review Video Module. In this medication review video module, Anne Feldman, NP, from the Cleveland Clinic Foundation, provides an in-depth overview of Guselkumab, an FDA-approved treatment for moderately to severely active ulcerative colitis. Anne explains the mechanism of action of Guselkumab, which is a dual-action monoclonal...
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.